Context Serum total and low-density lipoprotein (LDL) cholesterol contribute
significantly to atherosclerosis and its clinical sequelae. Previous analyses
of data from the National Health and Nutrition Examination Surveys (NHANES)
showed that mean levels of total cholesterol of US adults had declined from
1960-1962 to 1988-1994, and mean levels of LDL cholesterol (available beginning
in 1976) had declined between 1976-1980 and 1988-1994.
Objective To examine trends in serum lipid levels among US adults between 1960
and 2002, with a particular focus on changes since the 1988-1994 NHANES survey.
Design, Setting, and Participants Blood lipid measurements taken from 6098 to 15 719 adults who were
examined in 5 distinct cross-sectional surveys of the US population during
1960-1962, 1971-1974, 1976-1980, 1988-1994, and 1999-2002.
Main Outcome Measures Mean serum total cholesterol, LDL cholesterol, high-density lipoprotein
(HDL) cholesterol, and geometric mean serum triglyceride levels, and the percentage
of adults with a serum total cholesterol level of at least 240 mg/dL (≥6.22
mmol/L).
Results Between 1988-1994 and 1999-2002, total serum cholesterol level of adults
aged 20 years or older decreased from 206 mg/dL (5.34 mmol/L) to 203 mg/dL
(5.26 mmol/L) (P=.009) and LDL cholesterol levels
decreased from 129 mg/dL (3.34 mmol/L) to 123 mg/dL (3.19 mmol/L) (P<.001). Greater and significant decreases were observed in men
60 years or older and in women 50 years or older. The percentage of adults
with a total cholesterol level of at least 240 mg/dL (≥6.22 mmol/L) decreased
from 20% during 1988-1994 to 17% during 1999-2002 (P<.001).
There was no change in mean HDL cholesterol levels and a nonsignificant increase
in geometric mean serum triglyceride levels (P = .06).
Conclusions The decrease in total cholesterol level observed during 1960-1994 and
LDL cholesterol level observed during 1976-1994 has continued during 1999-2002
in men 60 to 74 years and women 50 to 74 years. The target value of no more
than 17% of US adults with a total cholesterol level of at least 240 mg/dL
(≥6.22 mmol/L), an objective of Healthy People 2010,
has been attained. The increase in the proportion of adults using lipid-lowering
medication, particularly in older age groups, likely contributed to the decreases
in total and LDL cholesterol levels observed. The increased prevalence of
obesity in the US population may have contributed to the increase in mean
serum triglyceride levels.
A number of epidemiological studies have investigated the association
between lipids and atherosclerotic disease. The Framingham Heart Study1 has assessed longitudinal trends in lipid levels and
their association with atherosclerotic disease, with data collection beginning
in 1948. Examples of other longitudinal studies in the United States are the
Atherosclerosis Risk in Communities study,2 the
Cardiovascular Heart Study,3 the Coronary Artery
Risk Development in Young Adults study,4 and
the Multi-Ethnic Study of Atherosclerosis.5
The Multinational Monitoring of Trends and Determinants in Cardiovascular
Disease study6 is an international study of
adults aged 35 to 64 years in 21 countries on 4 continents. In this study,
total cholesterol levels of adults aged 35 to 64 years showed a decline in
mean serum total cholesterol from the mid-1980s to the mid-1990s in approximately
half of the European populations included in the study.7
The National Health Examination Survey (NHES) and the National Health
and Nutrition Examination Surveys (NHANES) conducted by the National Center
for Health Statistics/Centers for Disease Control and Prevention (NCHS/CDC)
are unique among US studies. In NHANES, a wide battery of health-related data,
including serum lipids, were collected from a representative sample of the
US civilian noninstitutionalized population in standardized examinations.
Through these surveys, the NCHS/CDC has been obtaining population estimates
of serum total cholesterol since 1960 and high-density lipoprotein (HDL) cholesterol
and serum triglyceride since 1976.
Analysis of data from NHANES surveys has shown consistent declines in
the mean serum total cholesterol levels of adults and in the percentage of
adults with serum total cholesterol level of at least 240 mg/dL (≥6.22
mmol/L) between 1960 and 1994.8,9 Levels
of HDL cholesterol and very low-density lipoprotein cholesterol did not change
significantly in adults, suggesting that the decline in total cholesterol
levels was due to a decline in low-density lipoprotein (LDL) cholesterol levels
only. Recently, using data from NHANES 1999-2000, the study by Ford et al10 concluded that the rate of decline in mean serum
total cholesterol concentrations of the adult US population observed from
1960-1962 to 1988-1994 had slowed between 1988-1994 and 1999-2000.
During the 1990s, public health messages emphasized low saturated fat
and low cholesterol diets, maintenance of healthy weight, and increased physical
activity.11-13 Furthermore,
numerous clinical trials demonstrated the efficacy and safety of lipid-lowering
drugs, primarily statins, in reducing coronary heart disease (CHD) risk.14,15
Our goal was to present data on total cholesterol, LDL cholesterol,
HDL cholesterol, and serum triglyceride levels from NHANES 1999-2002, the
most recent NHANES survey, to evaluate trends in lipids between 1960 and 2002,
including the percentage with a serum total cholesterol level of at least
240 mg/dL (≥6.22 mmol/L), and to examine potential contributing factors
to the trends observed.
Design and Data Collection
NHANES and NHES constitute a series of cross-sectional, nationally representative,
area probability surveys conducted by the NCHS/CDC. The procedures for selecting
the sample and conducting the interviews and examinations for NHANES 1999-2002
were similar to the procedures for previous surveys.16 The
NHANES design is a stratified, multistage, probability sample. Detailed descriptions
of each survey have been published.17-20
Trends in mean serum total cholesterol for adults are based on comparisons
of data on adults aged 20 to 74 years from 5 surveys: NHES I (1960-1962) (n = 6098),
NHANES I (1971-1974) (n = 13 106), NHANES II (1976-1980) (n = 11 864),
NHANES III (1988-1994) (n = 13 914), and NHANES 1999-2002 (n = 7740).
Trends in triglyceride, HDL cholesterol, and LDL cholesterol levels (available
for NHANES II, NHANES III, and NHANES 1999-2002) are based on comparisons
of data from these 3 surveys.
Serum lipid levels were measured for adults aged 20 years or older in
NHANES III (n=15 719) and NHANES 1999-2002 (n=8809), but only for adults
20 to 74 years in previous surveys. Race/ethnicity categories are based on
self-reported data using the census categories from the Office of Management
and Budget directives.21 Estimates of mean
total and HDL cholesterol levels are based on all adults, regardless of fasting
state,11 examined during NHANES II (1976-1980),
NHANES III (1988-1994), and NHANES 1999-2002. Estimates of mean LDL and triglyceride
levels are based on adults who were examined in the morning and had fasted
for 8.5 to 23 hours.11 LDL cholesterol was
calculated using the Friedewald equation (serum total cholesterol−HDL
cholesterol−serum triglyceride/5) for examined persons with serum triglyceride
levels of 400 mg/dL or less (≤4.52 mmol/L).22
The overall response rates for adults aged 20 years or older on surveys
before NHANES 1999-2002 ranged from 64% to 84%.23-25 The
NHANES 1999-2002 data are based on 13 312 adults aged 20 years or older,
of whom 10 291 (77.3%) were interviewed and 9471 (71.1%) were interviewed,
underwent a physical examination, and were eligible for phlebotomy.
All lipid analyses were conducted on venous serum samples that were
frozen and shipped on dry ice to the laboratory conducting the lipid analyses.26 Methods for determining total cholesterol, HDL cholesterol,
and triglyceride levels for surveys before NHANES 1999-2002 have been described.8 Total cholesterol, HDL cholesterol, and triglyceride
measurements from each of the NHANES surveys were standardized according to
the criteria of the CDC or the National Heart, Lung, and Blood Institute Lipid
Standardization Program of the CDC.27 For NHANES
1999-2002, the total cholesterol, HDL cholesterol, and triglyceride methods
were calibrated using frozen serum calibration pools (Solomon Park Research
Laboratories, Kirkland, Wash), which had CDC-assigned reference values.
In NHANES 1999-2002, total cholesterol, HDL cholesterol, and triglyceride
methods were performed on an analyzer (Hitachi 704, Roche Diagnostics, Indianapolis,
Ind) at the Johns Hopkins University Lipoprotein Analytical Laboratory, Baltimore,
Md. Total cholesterol levels were measured using a coupled enzymatic reaction
based on a method by Allain et al (Roche Diagnostics).28 Triglyceride
levels were measured using a coupled enzymatic reaction based on a method
by Wahlefeld and Bergmeyer (Roche Diagnostics).29 HDL
cholesterol levels were measured using 2 methods. For the period 1999-2000,
a Heparin-Manganese precipitation method was used for most samples.30 A “direct” method of HDL cholesterol
(Roche Diagnostics)31,32 was used
for specimens with small sample volumes during 1999-2000 and for all samples
collected during 2001-2002. For 1999-2002, total cholesterol, triglyceride,
and direct HDL cholesterol levels met the National Cholesterol Education Program
(NCEP) performance goals for precision and bias.33-35 Precipitated
HDL cholesterol with a maximum precision of 4.5% and a bias up to 6.8% exceeded
the NCEP performance goals for HDL cholesterol (4% for precision and 5% for
bias). The HDL cholesterol was corrected for method bias for the NHANES 1999-2002
survey.36,37
Means and standard errors of the mean are presented for total, HDL,
and LDL cholesterol values. Geometric means and standard errors of geometric
means are presented for serum triglyceride levels because the distribution
is highly skewed. Sample weights, which account for the differential probabilities
of selection, nonresponse, and noncoverage are incorporated into the estimation
process. Final examined sample weights were used for total and HDL cholesterol
and morning fasting sample weights were used for triglyceride and LDL cholesterol
levels.38 The standard errors of the mean (or
percentages) were estimated by Taylor Series Linearization,39 a
method that incorporates the sample weights and accounts for the sample design.
Statistical hypotheses were tested at the α=.05 level of significance
using a t statistic.40 Multiple
comparisons were performed by using the Bonferroni method.41 This
method was applied by dividing .05 by number of implied comparisons. In testing
for race/ethnicity differences in means, geometric means, and percentages,
the overall level of .05 was divided by 3. For trends in serum total cholesterol
level of adults aged 20 to 74 years during 1960-2002, there were 10 implied
comparisons between any 2 of 5 surveys. For trends in LDL cholesterol, HDL
cholesterol, and serum triglyceride levels during 1976-2002, there were 3
implied comparisons between any 2 of 3 surveys. All data analyses were performed
by using the statistical packages SAS version 8.02 (SAS Institute, Cary, NC)
and SUDAAN version 8 (RTI, Research Triangle Park, NC).
Lipoprotein Levels, 1999-2002
Sample sizes for the various lipid measurements are shown in Table 1 and the age-adjusted and age-specific
means are presented in Table 2.22,42 The effects of age on mean total
cholesterol observed during NHES and previous NHANES surveys were also observed
during 1999-2002. Mean total cholesterol levels increased with age through
middle age and then decreased, reaching a peak at ages 50 to 59 years in men
and 60 to 69 years in women. Men had higher total cholesterol levels than
women for ages 30 to 49 years but lower levels after 60 years. Non-Hispanic
black men had lower age-adjusted mean total cholesterol levels than either
non-Hispanic white or Mexican American men. Mexican American women had lower
age-adjusted mean total cholesterol levels than non-Hispanic white women.
As in previous NHANES surveys, the effects of age on mean LDL cholesterol
levels were similar to those of mean total cholesterol. Men aged 30 to 49
years had higher mean LDL cholesterol levels than women of the same age, but
women aged 70 years or older had higher mean LDL cholesterol levels than men
of the same age. Non-Hispanic white and Mexican American but not non-Hispanic
black men had higher age-adjusted mean LDL cholesterol levels than women had
of similar race/ethnicity.
HDL cholesterol levels of women were consistently higher than those
levels of men. Among men, non-Hispanic black men had higher HDL cholesterol
levels than non-Hispanic white or Mexican American men. Among women, non-Hispanic
black women and white women had higher HDL cholesterol levels than Mexican
American women.
Serum triglyceride levels were lower in women than men among non-Hispanic
black and non-Hispanic white but not Mexican American adults. In men, serum
triglyceride levels were lower among non-Hispanic black men than non-Hispanic
white or Mexican American men. Among women, triglyceride levels were lowest
in non-Hispanic black women and highest in Mexican American women.
Trends in Serum Total Cholesterol Level, 1960-1962 to 1999-2002
Trends in age-adjusted and age-specific mean serum total cholesterol
levels of adults aged 20 to 74 years are presented for surveys 1960-1962 to
1999-2002, and values for adults aged 20 years or older are presented for
NHANES III (1988-1994) and NHANES 1999-2002 (Table 3).42 Between 1960-1962 and
1999-2002, the age-adjusted mean total cholesterol levels of adults aged 20
to 74 years decreased from 222 mg/dL (5.75 mmol/L) to 203 mg/dL (5.26 mmol/L)
in all adults (P<.001), from 220 mg/dL (5.70 mmol/L)
to 203 mg/dL (5.26 mmol/L) in men (P<.001), and
from 225 mg/dL (5.83 mmol/L) to 202 mg/dL (5.23 mmol/L) in women (P<.001). Mean total cholesterol levels decreased for each sex and
age group except for men and women aged 20 to 29 years. Between 1960-1962
and 1988-1994 and between 1976-1980 and 1988-1994, the age-adjusted mean total
cholesterol levels of adults aged 20 to 74 years decreased in all adults,
in both men and women.8,9 Between
1988-1994 and 1999-2002, total cholesterol levels of adults aged 20 to 74
years did not decrease significantly in all adults (204 vs 203 mg/dL [5.28
vs 5.26 mmol/L]), in men (204 vs 203 mg/dL [5.28 vs 5.26 mmol/L]), or in women
(205 vs 202 mg/dL [5.31 vs 5.23 mmol/L]).
With the availability of lipid data for adults 20 years or older for
the first time in 1988-1984, trends in serum total cholesterol levels for
adults 20 years or older between 1988-1994 and subsequent surveys are now
possible. Between 1988-1994 and 1999-2002, the age-adjusted mean serum total
cholesterol levels of adults 20 years or older decreased from 206 mg/dL (5.34
mmol/L) to 203 mg/dL (5.26 mmol/L) (P = .009)
in all adults, did not decrease significantly in men (204 vs 202 mg/dL [5.28
vs 5.23 mmol/L]), and decreased from 207 mg/dL (5.36 mmol/L) to 204 mg/dL
(5.28 mmol/L) in women (P=.009). Although the overall
reductions in total cholesterol levels were modest, the decreases observed
for men 60 years or older and for women 50 years or older were at least 10
mg/dL (≥0.26 mmol/L) and statistically significant.
Between 1960-1962 and 1999-2002, the mean serum total cholesterol level
of men ages 60 to 74 years decreased by 28 mg/dL (0.73 mmol/L) (232 vs 204
mg/dL [6.01 vs 5.28 mmol/L]). During this same period, there was a 40-mg/dL
(1.04 mmol/L) decrease for women ages 50 to 74 years (256 vs 216 mg/dL [6.63
vs 5.59 mmol/L] for women aged 50-59 years and 263 vs 223 mg/dL [6.81 vs 5.76
mmol/L] for women aged 60-74 years). Approximately one third of these reductions
occurred between 1988-1994 and 1999-2002.
Age-adjusted mean serum total cholesterol levels for adults aged 20
years or older between 1988-1994 and 1999-2002 are compared by race/ethnicity
and sex in Table 4.42 For
Mexican American and non-Hispanic white individuals, age-adjusted mean total
cholesterol levels decreased significantly in women only. For non-Hispanic
black individuals, a significant decrease in serum total cholesterol between
these 2 surveys was observed in both men and women.
The age-adjusted percentage of adults aged 20 years or older with a
serum total cholesterol level of at least 240 mg/dL (≥6.22 mmol/L)11 decreased from 20% (SE, 0.6) during 1988-1994 to 17% (SE, 0.6) during
1999-2002 (P<.001) (data not shown).43
Trends in LDL Cholesterol, HDL Cholesterol, and Serum Triglyceride
Levels, 1976-1980 to 1999-2002
In Table 5,22,42 age-adjusted
and age-specific mean LDL cholesterol, HDL cholesterol, and serum triglyceride
levels for adults aged 20 to 74 years are shown for the NHANES 1976-1980,
1988-1994, and 1999-2002 surveys, and for ages 20 years or older for the 1988-1994
and 1999-2002 surveys. Age-adjusted mean levels from the 2 most recent surveys
are compared by race/ethnicity and sex. Between 1976-1980 and 1988-1994, age-adjusted
mean LDL cholesterol levels decreased for all adults aged 20 to 74 years.
In more recent years, LDL cholesterol levels further decreased between 1988-1994
and 1999-2002 for all adults aged 20 to 74 years, for men 20 to 74 years,
for men 60 to 74 years, and for women 50 to 74 years but not for other sex
and age groups.
Between 1988-1994 and 1999-2002, the age-adjusted mean LDL cholesterol
level for adults aged 20 years or older decreased from 129 mg/dL (3.34 mmol/L)
to 123 mg/dL (3.19 mmol/L) in all adults (P<.001),
131 mg/dL (3.39 mmol/L) to 126 mg/dL (3.26 mmol/L) in men (P=.005), and 126 mg/dL (3.26 mmol/L) to 120 mg/dL (3.11 mmol/L) in
women (P<.001). Significant decreases were observed
in the oldest age group (≥75 years) for both men and women as well as in
men aged 60 to 74 years and in women aged 50 to 74 years. For ages 20 years
or older, the age-adjusted mean LDL cholesterol levels for non-Hispanic white
and non-Hispanic black adults decreased significantly between 1988-1994 and
1999-2002 for both men and women. For Mexican American adults, a significant
decrease was observed only for women.
During the years 1976-2002, HDL cholesterol levels did not change significantly
in men. In women, the age-adjusted mean HDL cholesterol level increased from
53.8 mg/dL (1.39 mmol/L) during 1976-1980 to 55.9 mg/dL (1.45 mmol/L) during
1999-2002 (P=.003). For women aged 60 to 74 years,
the mean HDL cholesterol level increased from 1976-1980 to 1988-1994 (P=.01) and from 1988-1994 to 1999-2002 (P=.005). An increase of 3.5 mg/dL (0.09 mmol/L) in HDL cholesterol
level between 1988-1994 and 1999-2002 was also observed in women aged 75 years
or older (P=.008).
Age-adjusted geometric mean serum triglyceride levels in adults aged
20 to 74 years increased from 116 mg/dL (1.31 mmol/L) during 1988-1994 to
122 mg/dL (1.38 mmol/L) during 1999-2002 (P=.04).
Between 1988-1994 and 1999-2002, the age-adjusted geometric mean serum triglyceride
level among adults aged 20 years or older increased from 118 mg/dL (1.33 mmol/L)
to 123 mg/dL (1.39 mmol/L), a difference that did not reach statistical significance
(P = .06).
Use of Cholesterol-Lowering Medications
Data on lipid-lowering medications are presented for adults 20 years
or older by sex and age and by sex and race/ethnicity for NHANES 1988-1994
and 1999-2002 in Table 6.42,44 The
age-adjusted percentage of adults 20 years or older on lipid-lowering medications
increased from 3.4% in 1988-1994 to 9.3% in 1999-2002 (P<.001). A significant increase also occurred for each race/ethnicity
and sex subgroup. The largest increase in the percentage of adults taking
lipid-lowering medication between 1988-1994 and 1999-2002 occurred in the
age group 60 years or older (6.8% to 24.3% in men and 8.7% to 21.6% in women).
Also, during 1988-1994 and 1999-2002, the proportion of adults taking lipid-lowering
medication was substantially higher in older adults (≥60 years) than in
younger adults (20-39 years). Race/ethnicity differences in the percentage
of adults taking lipid-lowering medications were observed during 1999-2002.
In men, the age-adjusted percentage taking lipid-lowering medication was highest
for non-Hispanic white men and lowest for Mexican American men. Among women,
the age-adjusted percentage on lipid-lowering medication was higher in non-Hispanic
white women than in non-Hispanic black women.
The age-adjusted mean total cholesterol level of adults 20 years or
older decreased from 206 mg/dL (5.34 mmol/L) in 1988-1994 to 203 mg/dL (5.26
mmol/L) in 1999-2002 (P=.009) and the age-adjusted
mean LDL cholesterol level decreased from 129 mg/dL (3.34 mmol/L) to 123 mg/dL
(3.19 mmol/L) during this same period (P<.001).
Significant and substantial declines in mean total and LDL cholesterol levels
were observed in men 60 years or older and women 50 years or older but not
in younger adults. In general, mean HDL cholesterol levels did not change
during this period. The age-adjusted geometric mean serum triglyceride level
of adults 20 years or older increased from 118 mg/dL (1.33 mmol/L) in 1988-1994
to 123 mg/dL (1.39 mmol/L) in 1999-2002 but was not statistically significant.
The age-adjusted percentage of adults 20 years or older with serum total cholesterol
level of at least 240 mg/dL (≥6.22 mmol/L) decreased from 20% to 17%, thereby
achieving one of the Healthy People 2010 objectives
(Objective 12-14).45
It has previously been reported that serum total and LDL cholesterol
levels among adults aged 20 to 74 years decreased from 1960-1962 to 1988-1994.8,9 Since 1994, these decreases have continued
but only in men aged 60 to 74 years and women aged 50 to 74 years. The age-adjusted
mean serum total cholesterol of adults aged 20 to 74 years did not change
significantly between 1988-1994 and 1999-2002 (204 vs 203 mg/dL [5.28 vs 5.26
mmol/L]). However, the age-adjusted mean LDL cholesterol level decreased from
128 mg/dL (3.32 mmol/L) in 1988-1994 to 123 mg/dL (3.19 mmol/L) in 1999-2002
(P<.001).
The use of cholesterol-lowering medication is likely to have contributed
to the decrease in total and LDL cholesterol observed predominantly in the
older age groups. Between 1988-1994 and 1999-2002, a series of clinical trials
with statins documented the benefit of cholesterol-lowering therapy.7,8,46-49 The
medical community appears to have accepted the results and their implications
for practice. Between 1995-1996 and 2001-2002, there was an increase in the
number of physician office visits and hospital visits of men and women aged
45 years or older with statins prescribed (P<.001).
Also, since the early 1990s, new categories of patients at high risk of CHD
events have been identified including those patients with existing CHD or
diabetes mellitus, and lower LDL cholesterol goals for such patients have
been established to decrease their CHD risk more effectively.11,50 Thus,
it is not surprising that the increase in usage of cholesterol-lowering medications
has occurred predominantly in older men and older women or that total and
LDL cholesterol levels have continued to decrease in these age groups.
A number of other lifestyle factors have been shown to be related to
lipid levels in adults, including dietary intake of saturated fat and cholesterol,
excess weight, and level of physical activity.11-13 In
both NHANES III and NHANES 1999-2002, data on these lifestyle factors as well
as a broad spectrum of other health-related data were collected.
Between 1988-1994 and 1999-2002, the combined prevalence of overweight
and obesity in adults aged 20 years or older increased from 55.9% to 65.1%
and the prevalence of obesity increased from 22.9% to 30.4%.51,52 These
increases could have contributed to the observed increase in mean triglyceride
levels, which tend to be increased in overweight individuals.53 Cross-sectional
studies suggest that increases in total and LDL cholesterol are associated
with increases in body mass index (calculated as weight in kilograms divided
by the square of height in meters)54,55 and
longitudinal studies suggest that increases in total cholesterol are also
associated with increases in body mass index.56,57
The decrease in total and LDL cholesterol in adults between 1976-1980
and 1988-1994 was consistent with documented decreases in dietary intake of
saturated fat and cholesterol.58 Between 1988-1994
and 1999-2002, the age-adjusted mean saturated fat intake as a percentage
of total calories for adults aged 20 years or older decreased slightly in
men (11.3% to 10.8% kcal; P<.001) and in women
(11.1% to 10.7% kcal; P=.006). The age-adjusted mean
dietary cholesterol intake decreased by only 7 mg/d in men (346 to 339 mg/d)
and increased by 11 mg/d in women (224 to 235 mg/d) (M.D.C., unpublished data,
2005).
The continued decrease of total and LDL cholesterol levels in older
adults is a positive trend. Clinical trial results suggest that a 1% decrease
in LDL cholesterol translates into a 1% decrease in relative risk for CHD.59 Between 1988-1994 and 1999-2002, the use of cholesterol-lowering
medication among older adults increased, although dietary data from NHANES
1999-2002 demonstrated only a small change in the overall intake of saturated
fat or cholesterol. It appears that the decreases in total and LDL cholesterol
may have been influenced more by increased medication use rather than by positive
lifestyle changes. Increasing prevalence of obesity among adults51,52 may
have contributed to a blunting in the decrease in total and LDL cholesterol
levels, as reflected in the observed trend toward increased triglyceride levels.
However, further research is needed to assess simultaneously the effects of
lipid-lowering medications and other lifestyle factors on lipids. The National
Heart, Lung, and Blood Institute’s NCEP recommends a healthy lifestyle,
which includes reducing intake of saturated fat and cholesterol, achieving
and maintaining healthy weight, and increasing physical activity for all adults,50 and regards additional efforts to promote such lifestyle
changes to be important for achieving further improvements in the population’s
lipid levels. Additional analyses of these critical population lifestyle factors
and lipid data are important. NHANES continues to monitor lipids and related
lifestyle factors of CHD in the US adult population.
Corresponding Author: Margaret D. Carroll,
MSPH, National Center for Health Statistics, Centers for Disease Control and
Prevention, 3311 Toledo Rd, Room 4413, Hyattsville, MD 20782 (mdc3@cdc.gov).
Author Contributions: Ms Carroll had full access
to all of the data in the study and takes responsibility for the integrity
of the data and the accuracy of the data analysis.
Study concept and design: Carroll, Lacher,
Cleeman.
Acquisition of data: Lacher, Johnson.
Analysis and interpretation of data: Carroll,
Lacher, Sorlie, Cleeman, Gordon, Wolz, Grundy.
Drafting of the manuscript: Carroll, Lacher,
Sorlie, Cleeman, Gordon, Wolz, Grundy.
Critical revision of the manuscript for important
intellectual content: Carroll, Lacher, Sorlie, Cleeman, Gordon, Wolz,
Grundy, Johnson.
Statistical analysis: Carroll, Lacher.
Obtained funding: Sorlie, Wolz.
Administrative, technical, or material support:
Carroll, Lacher, Wolz.
Study supervision: Carroll, Johnson.
Financial Disclosures: Dr Grundy receives research
grants funded by Merck, Abbott, Kos, and GlaxoSmithKline; is a consultant
for Pfizer, Abbott, Sanofi Aventis, and AstraZeneca; and receives honoraria
from Merck, Abbott, Kos, Bristol-Myers Squibb, and Schering Plough. No other
authors reported financial disclosures.
Funding/Support: This study was not supported
by external funding.
Acknowledgment: We thank Jeffery Hughes, MPH,
and John Powers, BA, for their voluntary assistance in the preparation of
the manuscript.
6.Tunstall-Pedoe H, . Monica: Monograph and Multimedia Sourcebook. Geneva, Switzerland: World Health Organization; 2003
8.Johnson CL, Rifkind BM, Sempos CT.
et al. Declining serum total cholesterol levels among US adults.
JAMA. 1993;269:3002-30088501842
Google ScholarCrossref 9. Health United States 1998 With Socioeconomic Status
and Chart Book. Hyattsville, Md: National Center for Health Statistics; 1998
10.Ford ES, Mokdad AH, Giles WH, Mensah GA. Serum total cholesterol concentrations and awareness, treatment, and
control of hypercholesterolemia among US adults.
Circulation. 2003;107:2185-218912719276
Google ScholarCrossref 11.National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation and Treatment
of High of High Blood Cholesterol in Adults (Adult Treatment Panel, II).
Circulation. 1994;89:1333-14458124825
Google ScholarCrossref 14.Downs JR, Clearfield M, Weis S.
et al. for the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men
and women with average cholesterol levels: results of AFCAPs/TexCAPS.
JAMA. 1998;279:1615-16229613910
Google ScholarCrossref 15.Shepherd J, Cobbe SM, Ford I.
et al. West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia.
N Engl J Med. 1995;333:1301-13077566020
Google ScholarCrossref 17. Plan and operation of the Third National Health and Nutrition Examination
Survey, 1988-1994, series 1: programs and collection procedures.
Vital Health Stat 1. 1994;;((32)):1-4077975354
Google Scholar 18.McDowell A, Engel A, Massey JT, Maurer K. Plan and operation of the Second National Health and Nutrition Examination
Survey, 1976-1980.
Vital Health Stat 1. 1981;Series 1((15)):1-1447344293
Google Scholar 19.Miller HW. Plan and operation of the Health and Nutrition Examination Survey,
United States: 1971-1973.
Vital Health Stat 1. 1973;1(10A):1-464347506
Google Scholar 20. Plan and initial program of the Health Examination Survey.
Vital Health Stat 1. 1965;4:1-435294776
Google Scholar 22.Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol
in plasma without use of the preparative ultracentrifuge.
Clin Chem. 1972;18:499-5024337382
Google Scholar 23.Forthofer RN. Investigations of nonresponse bias in NHANES II.
Am J Epidemiol. 1983;117:507-5156837562
Google Scholar 24. A Comparison and Analysis of Examined and Nonexamined
Persons on Medical History Characteristics for the First Round of the Health
and Nutrition Examination Survey. Washington, DC: US Dept of Health, Education, and Welfare; 1974
25.Miller H, Williams P. Factors related to response in a health examination survey, United
States: 1960-1962.
Vital Health Stat 1. 1969;2:(36)
1-485306696
Google Scholar 27.Myers GL, Cooper GR, Winn CL, Smith SJ. The Centers for Disease Control: National Heart, Lung, and Blood Institute
Lipid Standardization Program.
Clin Lab Med. 1989;9:105-1352538292
Google Scholar 28.Allain CC, Poon LS, Chan CSG, Richmond W, Fu PC. Enzymatic determination of total serum cholesterol.
Clin Chem. 1974;20:470-4754818200
Google Scholar 29.Wahlefeld A, , Bergmeyer HU, . Methods of Enzymatic Analysis. 2nd ed. New York, NY: Academic Press; 1974:1831
30.Bachorik PS, Walker RE, Virgil DG. High-density lipoprotein cholesterol in heparin-MnCl
2 supernates
determined with the Dow enzymic method after precipitation of −Mn
2+ with HCO
3.
Clin Chem. 1984;30:839-8426327118
Google Scholar 31.Sugiuchi H, Uji Y, Okabe H.
et al. Direct measurement of high-density lipoprotein cholesterol in serum
with polyethylene glycol-modified enzymes and sulfated α-cyclodextrin.
Clin Chem. 1995;41:717-7237729051
Google Scholar 32.Matsuzaki Y, Kawaguchi E, Morita Y.
et al. Evaluation of two kinds of reagents for direct determination of HDL
cholesterol.
J Anal Bio Sc. 1996;19:419-427
Google Scholar 33. Current status of blood cholesterol measurement in clinical laboratories
in the United States: a report from the Laboratory Standardization Panel of
the National Cholesterol Education Program.
Clin Chem. 1988;34:193-2013338168
Google Scholar 34.Stein EA, Myers GL.National Cholesterol Education Program Working Group on Lipoprotein
Measurement. National Cholesterol Education Program recommendations for triglyceride
measurement.
Clin Chem. 1995;41:1421-14267586511
Google Scholar 35.Warnick GR, Wood PD.National Cholesterol Education Program Working Group on Lipoprotein
Measurement. National Cholesterol Education Program recommendations for measurement
of high-density lipoprotein cholesterol.
Clin Chem. 1995;41:1427-14337586512
Google Scholar 39.Wolter KM. Chapter 6: Variance Estimation. New York, NY: Springer-Verlag; 1990
40.Korn EL, Graubaurd BI. Analysis of Health Surveys. New York, NY: Wiley; 1999:75-76
41.Miller RG. Developments in multiple comparisons, 1966-1976.
J Am Stat Assoc. 1977;72:779-788
Google Scholar 43.National Center for Health Statistics. Health, United States, 2004 With Chartbook on Trends
in the Health of Americans. Hyattsville, Md: US Dept of Health and Human Services; 2004
45. Healthy People 2010. 2nd ed. Washington, DC: US Dept of Health and Human Services; 2000
46.Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary
heart disease.
Lancet. 1994;344:1383-13897968073
Google Scholar 47.Sacks FM, Pfeffer MA, Moye LA.
et al. Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction
in patients with average cholesterol levels.
N Engl J Med. 1996;335:1001-10098801446
Google ScholarCrossref 48.The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID)
Study Group. Prevention of cardiovascular events and death with pravastatin in patients
with coronary heart disease and a broad range of initial cholesterol levels.
N Engl J Med. 1998;339:1349-13579841303
Google ScholarCrossref 49.LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized
controlled trials.
JAMA. 1999;282:2340-234610612322
Google ScholarCrossref 50.National Cholesterol Education Program (NCEP) Expert Panel on Detection,
Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment
Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert
Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in
Adults (Adult Treatment Panel III) final report.
Circulation. 2002;106:3143-342112485966
Google Scholar 51.Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among adults, 1999-2000.
JAMA. 2002;288:1723-172712365955
Google ScholarCrossref 52.Hedley AA, Ogden CL, Johnson CL, Carroll MD, Curtin LR, Flegal KM. Prevalence of overweight and obesity among US children, adolescents
and adults, 1999-2002.
JAMA. 2004;291:2847-285015199035
Google ScholarCrossref 53.NHLBI Expert Panel on the Identification, Evaluation, and Treatment
of Overweight and Obesity in Adults. Clinical guidelines on the identification, evaluation, and treatment
of overweight and obesity in adults.
Obes Res. 1998;6:(suppl 2)
51S-209S9813653
Google ScholarCrossref 54.Denke MA, Sempos CT, Grundy SM. Excess body weight: an under-recognized contributor to high blood cholesterol
levels in white American men.
Arch Intern Med. 1993;153:1093-11038481076
Google ScholarCrossref 55.Denke MA, Sempos CT, Grundy SM. Excess body weight to dyslipidemia in white American women.
Arch Intern Med. 1994;154:401-4108117172
Google ScholarCrossref 56.Ashley FW Jr, Kannel WB. Relation of weight change to changes in atherogenic traits: the Framingham
Study.
J Chronic Dis. 1974;27:103-1144830839
Google ScholarCrossref 57.Hershcopf RJ, Elahi D, Andres R.
et al. Longitudinal changes in serum cholesterol in men.
J Chronic Dis. 1982;35:101-1147056835
Google ScholarCrossref 58.Ernst ND, Sempos CT, Briefel RR, Clark MB. Consistency between US dietary fat and serum total cholesterol concentrations.
Am J Clin Nutr. 1997;66:(suppl)
965S-972S9322575
Google Scholar 59.Grundy SM, Cleeman JI, Bairey Merz CN.
et al. Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol
Education Program Adult Treatment Panel III Guidelines.
Circulation. 2004;110:227-23915249516
Google ScholarCrossref